Shots: The FDA approval is based on P-III study assessing Dupixent + TCS vs TCS as monothx. in children with severe AD. In the trial, children treated with Dupixent and […]readmore
Tags : Approval as First Biologic for Children Aged 6-11 Years with Moderate-to-Severe Atopic Dermatitis